Invenomic Capital Management LP Has $20.16 Million Holdings in Enovis Corporation $ENOV

Invenomic Capital Management LP lifted its holdings in Enovis Corporation (NYSE:ENOV) by 6.2% during the 4th quarter, Holdings Channel reports. The fund owned 756,717 shares of the company’s stock after acquiring an additional 44,048 shares during the quarter. Invenomic Capital Management LP’s holdings in Enovis were worth $20,159,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of ENOV. Arax Advisory Partners acquired a new position in Enovis during the 4th quarter worth $29,000. EverSource Wealth Advisors LLC lifted its holdings in Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after buying an additional 707 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Enovis by 353.5% during the 4th quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock worth $49,000 after buying an additional 1,446 shares in the last quarter. Danske Bank A S acquired a new position in Enovis during the 3rd quarter worth $64,000. Finally, iSAM Funds UK Ltd acquired a new position in Enovis during the 3rd quarter worth $80,000. 98.45% of the stock is owned by institutional investors and hedge funds.

Enovis Stock Performance

ENOV stock opened at $20.83 on Thursday. The business’s fifty day moving average is $23.94 and its 200-day moving average is $24.37. The company has a quick ratio of 1.05, a current ratio of 2.04 and a debt-to-equity ratio of 0.87. The company has a market cap of $1.20 billion, a P/E ratio of -1.05 and a beta of 1.38. Enovis Corporation has a twelve month low of $20.55 and a twelve month high of $36.82.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. The company had revenue of $589.15 million for the quarter, compared to the consensus estimate of $572.02 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The firm’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.81 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities research analysts forecast that Enovis Corporation will post 3.65 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. William Blair assumed coverage on Enovis in a report on Friday, April 17th. They set an “outperform” rating on the stock. BTIG Research reaffirmed a “buy” rating and set a $39.00 price objective on shares of Enovis in a report on Friday, May 22nd. Wall Street Zen downgraded Enovis from a “buy” rating to a “hold” rating in a report on Saturday, June 6th. Zacks Research downgraded Enovis from a “strong-buy” rating to a “hold” rating in a report on Monday, June 1st. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Enovis in a report on Friday, April 10th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $44.50.

Insider Buying and Selling at Enovis

In related news, insider Oliver Engert purchased 1,200 shares of the business’s stock in a transaction dated Thursday, June 11th. The shares were bought at an average price of $21.62 per share, with a total value of $25,944.00. Following the purchase, the insider directly owned 51,840 shares in the company, valued at $1,120,780.80. This trade represents a 2.37% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Over the last 90 days, insiders acquired 4,200 shares of company stock valued at $92,084. Corporate insiders own 2.90% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.